GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Apr 2011 07:00

RNS Number : 1957E
ViaLogy PLC
04 April 2011
 



VIALOGY PLC ("VIALOGY" or "THE COMPANY")

 

TRADING UPDATE

QUARTERLY BUSINESS HIGHLIGHTS

 

London, April 4, 2011, ViaLogy PLC (LSE: VIY). ViaLogy reports the following business highlights for the quarter ending March 31.

ViaLogy has made significant progress in its strategy of winning major global oil and gas industry clients, applying QuantumRD in major onshore and offshore exploration and development projects, and positioning QuantumRD as an accepted risk reduction technology in the industry's mainstream. Having completed technical discussions and successfully concluded technology demonstration projects, detailed contract proposals have been requested and submitted both to a Fortune Global 500 E&P firm and a major National OilCompany. ViaLogy's work should complement and enhance industry tools, and the Board's intention is that it should also establish both price and revenue levels for its QuantumRD technology. Successful application of the technology could spell capital expenditure savings as well as more accurate drilling locations for the two clients. Contract timing will depend in part on government approval for work in national lease properties and specific contract terms and conditions.

Under a previously announced contract ViaLogy has analysis underway on seismic data provided for a prospect owned by a supermajor company.

ViaLogy has also launched a development project to extend the use of Quantum Resonance Interferometry (QRI), its fundamental patented IP, to the shale gas microseismic market. This rapidly developing market segment utilises seismic data to monitor subsurface activity during the fracturing process, a key step in the production of natural gas. Vast natural gas deposits in the US and elsewhere will depend upon microseismic analysis for extraction. ViaLogy believes its weak signal detection technology, and its ability to detect subtle fractures, can both reduce costs and facilitate production. Natural gas is projected to account for 24% of the global energy supply by 2020 and shale gas is expected to account for over 64% of the natural gas in the US by 2020.  ViaLogy is pursuing this work in conjunction with an international oilfield services company.

 

ViaLogy recently received notice that its QRI technology patent has been officially allowed in China, an important step in protecting ViaLogy's future market position in that country. Patents have already been issued in the US and Europe.

In an update to the January announcement reporting a successful well based on QuantumRD analysis, initial production has been established at over 100 barrels per day. Hydrocarbon zone depths and porosities conform to ViaLogy's projections.

CEO Robert Dean commented, "ViaLogy continues to make impressive progress as measured against our ambitious business objectives. For over a year most of our limited resources have been focused on further development of the technology, on demonstrating its use as a risk-reduction tool in the context of an accepted industry workflow suite, and its application and efficacy in tough exploration prospects by clients whose recognition will be critical to business growth. Pre-contract work for our prospective clients has contributed to a real spirit of partnership. Also, the importance of natural gas as a current and future energy source has convinced us that we have to devote effort to enter this adjacent market for our technology." 

For further information contact:

 

ViaLogy PLC

 

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

 

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 207 107 8000

 

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 207 107 8000

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKXLFBFZFLBBV
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.